Furthermore, BDMC and cisplatin co-treatment regulates the chemo-sensitivity response for cisplatin-resistant NSCLC by repressing the expression of CA916798 and PI3K/AKT activities [148]. Here, AKT1 is linked to non-small cell lung carcinoma.